ERBB2 and breast carcinoma: In September 2022, the DAWNA-2 trial released fresh findings at the European Society for Medical Oncology (ESMO), comparing Dalpiciclib plus AI with placebo for endocrine-sensitive HR + /HER2- advanced breast cancer.